ZYX

Across TCGA pan-cancer cohorts, ZYX mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZYX data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZYX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZYX expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where ZYX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
CCRCC	DFS	Median	All	0.519	0.832	.017	9	view →
LSCC	OS	Median	II,III,IV	0.678	0.869	.025	5	view →
LUAD	DFS	Tertile	All	0.729	0.441	.042	3	view →
HNSC	DFS	Median	III,IV	0.472	0.737	.017	3	view →
GBM	DFS	Median	All	0.635	0.795	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZYX–PDAC (DFS)

Open the PDAC breakdown →